Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Mar 19

2021

Hua Medicine Announces 2020 Annual Results

Hua Medicine (the"Company", Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). During the Reporting Period, the Company continued to advance various clinical trials and R&D investments, successfully completed two Phase III registration trials for dorzagliatin in China, and achieved remarkable results in preparing for dorzagliatin's commercialization.

Dec 18

2020

Hua Medicine Successfully Completes Its Registration Phase III Trials. Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

Hua Medicine (the"Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced

Dec 17

2020

Hua Medicine Announces the Commercialization Cooperation with Raybow Pharmaceutical

Hua Medicine (the "Company", Stock Code: 2552.HK) today announces that it has entered into a commercial supply agreement with Zhejiang Raybow Pharmaceutical Co., Ltd. ("Raybow Pharmaceutical"). As a future major supplier of dorzagliatin, the global first-in-class oral drug for the treatment of Type 2 diabetes, Raybow Pharmaceutical will supply Hua Medicine with active pharmaceutical ingredients ("API") after the commercial launch of dorzagliatin in China.

Nov 26

2020

Hua Medicine's Dorzagliatin Announces Additional Data to be Presented at CDS 2020

Hua Medicine (the"Company", Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced additional analysis results from dorzagliatin’s 24-week metformin combination registration trial DAWN, (also known as HMM0302).

Oct 14

2020

Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin

Hua Medicine (the"Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder (“MAH”) system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.

Aug 17

2020

Bayer and Hua Medicine announce commercialization agreement

Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China

Aug 17

2020

Hua Medicine Announces 2020 Interim Results

Hua Medicine (the"Company", Stock Code: 2552.HK), a global innovative drug research and development company focused on the novel therapies for the treatment of Type 2 Diabetes (“T2D”), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2020 (the “Reporting Period”).

Jul 01

2020

Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin

Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes.

Jun 18

2020

Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial

Hua Medicine (the"Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301), the first Phase III trial with dorzagliatin.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.